To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in
order to determine if there is less global brain atrophy over one year, as measured by
ventricular enlargement as a primary outcome measure, when patients are randomized to
treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting
enzyme inhibitor (ACEI).
This study uses a simple validated measure of brain atrophy as a surrogate marker in a
repurposing effort that could recast an antihypertensive medication as a cognitive
enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and
patients at risk for AD. If the proof of concept result is positive, a larger study would be
warranted with potential practice-changing impact.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.